TD Asset Management Inc Has $13.35 Million Stake in Krystal Biotech, Inc. $KRYS

TD Asset Management Inc boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 20.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 54,142 shares of the company’s stock after purchasing an additional 9,062 shares during the period. TD Asset Management Inc’s holdings in Krystal Biotech were worth $13,348,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Optimize Financial Inc lifted its holdings in Krystal Biotech by 1.4% in the fourth quarter. Optimize Financial Inc now owns 2,855 shares of the company’s stock valued at $704,000 after buying an additional 40 shares during the period. Perigon Wealth Management LLC lifted its holdings in Krystal Biotech by 0.5% in the fourth quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock valued at $2,211,000 after buying an additional 41 shares during the period. Crossmark Global Holdings Inc. lifted its holdings in Krystal Biotech by 2.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,124 shares of the company’s stock valued at $524,000 after buying an additional 55 shares during the period. Sound View Wealth Advisors Group LLC lifted its holdings in Krystal Biotech by 2.9% in the third quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock valued at $354,000 after buying an additional 56 shares during the period. Finally, Oregon Public Employees Retirement Fund lifted its holdings in Krystal Biotech by 1.0% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 5,896 shares of the company’s stock valued at $1,454,000 after buying an additional 57 shares during the period. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity

In other news, EVP John Charles Thomas sold 642 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $302.03, for a total transaction of $193,903.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.10% of the company’s stock.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $301.76 on Tuesday. The firm has a 50-day moving average of $283.40 and a 200-day moving average of $265.26. The company has a market cap of $8.90 billion, a PE ratio of 40.34 and a beta of 0.53. Krystal Biotech, Inc. has a one year low of $127.99 and a one year high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. On average, equities research analysts expect that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on KRYS. Chardan Capital boosted their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Citigroup boosted their target price on shares of Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a report on Tuesday, May 5th. Weiss Ratings upgraded shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, April 9th. HC Wainwright restated a “buy” rating and issued a $310.00 target price on shares of Krystal Biotech in a report on Monday, June 1st. Finally, Guggenheim upped their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $324.11.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.